Elicio Therapeutics (ELTX) Net Income (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Net Income came in at -$22.0 million in Q1 2026, down 102.55% YoY from $862.4 million in Q1 2025, and down 139.62% on a QoQ basis from -$9.2 million in Q4 2025.
Elicio Therapeutics (ELTX) Net Income (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Net Income data on file, last reported at -$22.0 million in Q1 2026.
- Quarterly Net Income fell 102.55% year-over-year to -$22.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.2 million (down 25.28% YoY) and the FY2025 annual result came in at -$42.8 million, up 70.52% from the prior year.
- Net Income fell to -$22.0 million in Q1 2026, from -$9.2 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$6.1 million in Q4 2022 to a low of -$22.0 million in Q1 2026.
- A 5-year average of -$12.8 million and a median of -$10.9 million in 2025 frame the typical range for Net Income.
- The widest YoY moves for Net Income: up 83.5% in 2022, down 142.28% in 2022.
- Tracing ELTX's Net Income over 5 years: stood at -$6.1 million in 2022, then sank by 61.41% to -$9.8 million in 2023, then tumbled by 31.37% to -$12.8 million in 2024, then grew by 28.48% to -$9.2 million in 2025, then sank by 139.62% to -$22.0 million in 2026.
- The last three Net Income figures came in at -$22.0 million (Q1 2026), -$9.2 million (Q4 2025), and -$18.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | -10.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.64 Mn |
| Mar 31, 2026 | -22.00 Mn |
| Dec 31, 2025 | -9.18 Mn |
| Sep 30, 2025 | -18.37 Mn |
| Jun 30, 2025 | -16.64 Mn |
| Mar 31, 2025 | -10.86 Mn |
| Dec 31, 2024 | -12.84 Mn |
| Sep 30, 2024 | -10.30 Mn |
| Jun 30, 2024 | -18.84 Mn |
| Mar 31, 2024 | -10.62 Mn |
| Dec 31, 2023 | -9.77 Mn |
| Sep 30, 2023 | -19.72 Mn |
| Jun 30, 2023 | -11.25 Mn |
| Mar 31, 2023 | -8.15 Mn |
| Dec 31, 2022 | -6.05 Mn |
| Sep 30, 2022 | -10.23 Mn |
| Jun 30, 2022 | -7.34 Mn |
| Mar 31, 2022 | -14.81 Mn |
| Dec 31, 2021 | 14.32 Mn |
| Sep 30, 2021 | -41.04 Mn |